Literature DB >> 29623652

Baloxavir: First Global Approval.

Young-A Heo1.   

Abstract

Baloxavir marboxil (Xofluza™; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections. Phase III development is underway in the USA, EU and other countries for this indication. This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29623652     DOI： 10.1007/s40265-018-0899-1

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  2 in total

Review 1.  Influenza antivirals currently in late-phase clinical trial.

Authors:  Paulina Koszalka; Danielle Tilmanis; Aeron C Hurt
Journal:  Influenza Other Respir Viruses       Date:  2017-02-28       Impact factor: 4.380

2.  Strategies for mitigating an influenza pandemic.

Authors:  Neil M Ferguson; Derek A T Cummings; Christophe Fraser; James C Cajka; Philip C Cooley; Donald S Burke
Journal:  Nature       Date:  2006-04-26       Impact factor: 49.962
  2 in total
  38 in total

Review 1.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

2.  Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials.

Authors:  Lei Zhao; Yunzheng Yan; Qingsong Dai; Xingzhou Li; Ke Xu; Gang Zou; Keyu Yang; Wei Li; Xiaojia Guo; Jingjing Yang; Yuexiang Li; Qing Xia; Ruiyuan Cao; Wu Zhong
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.

Authors:  Liva Checkmahomed; Zeineb M'hamdi; Julie Carbonneau; Marie-Christine Venable; Mariana Baz; Yacine Abed; Guy Boivin
Journal:  J Infect Dis       Date:  2020-01-01       Impact factor: 5.226

4.  Prophylaxis in healthcare workers during a pandemic: a model for a multi-centre international randomised controlled trial using Bayesian analyses.

Authors:  Pepa Bruce; Kate Ainscough; Lee Hatter; Irene Braithwaite; Lindsay R Berry; Mark Fitzgerald; Thomas Hills; Kathy Brickell; David Cosgrave; Alex Semprini; Susan Morpeth; Scott Berry; Peter Doran; Paul Young; Richard Beasley; Alistair Nichol
Journal:  Trials       Date:  2022-06-27       Impact factor: 2.728

5.  Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.

Authors:  Cy V Credille; Benjamin L Dick; Christine N Morrison; Ryjul W Stokes; Rebecca N Adamek; Nicholas C Wu; Ian A Wilson; Seth M Cohen
Journal:  J Med Chem       Date:  2018-10-31       Impact factor: 7.446

6.  Pulmonary surfactant lipids inhibit infections with the pandemic H1N1 influenza virus in several animal models.

Authors:  Mari Numata; James R Mitchell; Jennifer L Tipper; Jeffrey D Brand; John E Trombley; Yoji Nagashima; Pitchaimani Kandasamy; Hong Wei Chu; Kevin S Harrod; Dennis R Voelker
Journal:  J Biol Chem       Date:  2019-12-27       Impact factor: 5.157

7.  Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.

Authors:  Jeremy C Jones; Philippe Noriel Q Pascua; Thomas P Fabrizio; Bindumadhav M Marathe; Patrick Seiler; Subrata Barman; Richard J Webby; Robert G Webster; Elena A Govorkova
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-26       Impact factor: 11.205

8.  Detection of swine influenza virus in nasal specimens by reverse transcription-loop-mediated isothermal amplification (RT-LAMP).

Authors:  Abhijeet A Bakre; Les P Jones; Hailey K Bennett; Davis E Bobbitt; Ralph A Tripp
Journal:  J Virol Methods       Date:  2020-11-30       Impact factor: 2.014

9.  Optimization of 4-Aminopiperidines as Inhibitors of Influenza A Viral Entry That Are Synergistic with Oseltamivir.

Authors:  Irina N Gaisina; Norton P Peet; Han Cheng; Ping Li; Ruikun Du; Qinghua Cui; Kevin Furlong; Balaji Manicassamy; Michael Caffrey; Gregory R J Thatcher; Lijun Rong
Journal:  J Med Chem       Date:  2020-03-02       Impact factor: 7.446

10.  Expanding medicinal chemistry into 3D space: metallofragments as 3D scaffolds for fragment-based drug discovery.

Authors:  Christine N Morrison; Kathleen E Prosser; Ryjul W Stokes; Anna Cordes; Nils Metzler-Nolte; Seth M Cohen
Journal:  Chem Sci       Date:  2019-12-12       Impact factor: 9.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.